Please login to the form below

Not currently logged in
Email:
Password:

GSK to cut 3,000 jobs

GlaxoSmithKline is to announce more than 3,000 job cuts at its European and US operations as a result of a shift in focus to emerging markets

It is reported that GlaxoSmithKline is to announce more than 3,000 job cuts at its European and US operations as a result of a shift in focus from stagnant Western markets to China in particular, and emerging markets in Asia and Latin America.

GSK aims to reduce £1.7bn in annual costs by the end of next year and re-focus efforts on research and development. Demand for the company's Pandremix vaccine against H1N1 has been lower than anticipated and sales of GSK's H1N1 drug Relenza have also fallen short.

Analysts have said that the group is too reliant on aging patents – the company has been hit most recently by generic versions of its herpes treatment Valtrex after expiry of its US patent.

1st February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
FleishmanHillard Fishburn

Improving patient outcomes, global health and healthcare systems Our global network of more than 300 healthcare counselors provides seamless collaboration...

Latest intelligence

Artificial Intelligence: the new healthcare algorithm
The age of computers has hugely evolved, and with the emergence of effective machine learning, pattern recognition, and decision-making algorithms, Artificial Intelligence provides a revolutionary new approach to tailored healthcare....
Choosing destiny
As our market transforms, firms must choose their new business model carefully...
Market access improvements in Turkey
...

Infographics